SYNCROSOME (ETAP SA)

SYNCROSOME is part of ETAP-LAB, an independent contract research organization (CRO) providing preclinical pharmacology and research services, as well as scientific expertise to Pharmaceutical, biotech and medtech companies. With 35+ years of expertise, we are a recognized European player with proven track-record of success to produce high-quality translationnal data and offering efficient, cost-effective services across four preclinical therapeutic expertise.

Our main Services:

• Efficacy studies in CNS (BRAINXPLORE), STROKE (STROK@LLIANCE), CARDIOLOGY (SYNCROSOME) and DERMATOLOGY (SKINAXIS), from hit-to-lead to PK/PD and pre-IND in vivo pharmacology.

• Extensive portfolio of both IN VITRO and IN VIVO models, plus bioanalytical services (ELISA, WB, multiplexed assays, IHC) and high‑performance imaging (MRI, PET-Scan, MPI, echocardiography, fUS, HCS).

• Innovative approaches—including human cell culture models, in vivo models, and alternative methods (NAMs like BRAIN-ON-CHIP-based models of CNS deseases).

Working with ETAP-LAB - a trusted preclinical service provider that you can rely on:

• Responsive and meticulous customer service. Top priority to customer satisfaction (CSAT 2024: 100%).

• A portfolio of over 100 tried-and-tested in vitro and in vivo reference models at the right price, with optimized study designs

• Capacity of 60 to 80 projects conducted each year for customers

• Personalized support with qualified and efficient staff (~45 employees)

• Reducing the experimental, statistical, and regulatory risks of your programs

• Delivering data with high translational value, relevant to your decision-making

• A holistic ethical conduct and transparency

• ISO9001 quality approach - Scientist.com & Science Exchange registered supplier

We enhance the value of your assets and help you convince investors, key opinion leaders, and regulatory bodies. Let's schedule a meeting!